Literature DB >> 12518707

Multiple-pool cell lifespan model of hematologic effects of anticancer agents.

Wojciech Krzyzanski1, William J Jusko.   

Abstract

The leukopenic effects of anticancer agents are described using a semi-physiologic multiple-pool cell lifespan model. The time course of myelosuppression in relation to the drug concentration vs. time profile was characterized using a three pool indirect model. The proliferation and maturation stages of myeloid cells in the bone marrow and cell removal from the circulation were quantitated with a cell life-span concept. Drug effects were assumed to take place in the bone marrow based on irreversible linear or capacity-limited cytotoxicity. Mathematical derivations and computer simulations (Adapt II) were used to examine the properties of the model. Data from the literature were also analyzed. Cell response profiles after therapy typically exhibit a lag period, reduction to a nadir, and return to baseline. The predicted values of the time periods of granulopoiesis were 10-14 days for proliferation, and 1-6 days for maturation of progenitor cells in the bone marrow. The proposed irreversible mechanism of cell killing by anticancer drugs explains previously observed relationships between leukocyte nadir counts and exposure to the drug and/or duration of drug concentrations above some threshold level. The model was applied to literature data for paclitaxel and etoposide effects on leukocyte counts. The predicted value of KC50 for paclitaxel ranged from 0.004 to 0.2 microgram/mL and for etoposide 2 micrograms/mL. The present model accounts for drug-induced leukopenia using a physiologic cell production and loss model and irreversible cytotoxicity in a precursor pool.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12518707     DOI: 10.1023/a:1020984823092

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  24 in total

1.  Asymptotics of the total net direct pharmacological effect for large drug doses.

Authors:  W Krzyzanski
Journal:  J Math Biol       Date:  2000-12       Impact factor: 2.259

Review 2.  Hematopoietic stem cells.

Authors:  E Gunsilius; G Gastl; A L Petzer
Journal:  Biomed Pharmacother       Date:  2001-05       Impact factor: 6.529

3.  Kinetic model of a bone-marrow stem-cell population.

Authors:  L G LAJTHA; R OLIVER; C W GURNEY
Journal:  Br J Haematol       Date:  1962-10       Impact factor: 6.998

4.  Paclitaxel pharmacodynamics: application of a mechanism-based neutropenia model.

Authors:  G J Fetterly; J M Tamburlin; R M Straubinger
Journal:  Biopharm Drug Dispos       Date:  2001-09       Impact factor: 1.627

5.  Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents.

Authors:  W J Jusko
Journal:  J Pharm Sci       Date:  1971-06       Impact factor: 3.534

6.  Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats.

Authors:  L E Friberg; A Freijs; M Sandström; M O Karlsson
Journal:  J Pharmacol Exp Ther       Date:  2000-11       Impact factor: 4.030

7.  A program package for simulation and parameter estimation in pharmacokinetic systems.

Authors:  D Z D'Argenio; A Schumitzky
Journal:  Comput Programs Biomed       Date:  1979-03

8.  Analysis of antiplatelet effect of ticlopidine in humans: modeling based on irreversible inhibition of platelet precursors in bone marrow.

Authors:  M Katashima; Y Yamada; K Yamamoto; H Kotaki; H Sato; Y Sawada; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1999-06

9.  Randomized trial of filgrastim vs. sequential filgrastim and molgramostim after dose-intensified carboplatin, cyclophosphamide, and etoposide: a phase I pilot study.

Authors:  F Recchia; S De Filippis; P Torchio; S Rea; A Gulino; D Quaglino; L Frati
Journal:  Am J Clin Oncol       Date:  1997-04       Impact factor: 2.339

10.  Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.

Authors:  T Ohtsu; Y Sasaki; T Tamura; Y Miyata; H Nakanomyo; Y Nishiwaki; N Saijo
Journal:  Clin Cancer Res       Date:  1995-06       Impact factor: 12.531

View more
  16 in total

Review 1.  Pharmacodynamic models of age-structured cell populations.

Authors:  Wojciech Krzyzanski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-16       Impact factor: 2.745

2.  Population cell life span models for effects of drugs following indirect mechanisms of action.

Authors:  Juan J Perez-Ruixo; Hui C Kimko; Andrew T Chow; Vladimir Piotrovsky; Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

3.  An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics.

Authors:  C Meille; A Iliadis; D Barbolosi; N Frances; G Freyer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-12-24       Impact factor: 2.745

4.  Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells.

Authors:  Wojciech Krzyzanski; Juan Jose Perez-Ruixo; An Vermeulen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-06-13       Impact factor: 2.745

Review 5.  Lifespan based indirect response models.

Authors:  Wojciech Krzyzanski; Juan Jose Perez Ruixo
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-01-03       Impact factor: 2.745

6.  Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models.

Authors:  Wojciech Krzyzanski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-24       Impact factor: 2.745

7.  Interactions of prednisolone and other immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assays.

Authors:  Mohamed A Kamal; William J Jusko
Journal:  J Clin Pharmacol       Date:  2004-09       Impact factor: 3.126

8.  Pharmacokinetics and toxicity of repeated oral etoposide is altered by morphine coadministration in rats.

Authors:  Makoto Miyazaki; Tomoko Kawase; Chisako Nishimura; Tomoko Kitamura; Kazunori Iwanaga; Masawo Kakemi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-06-27       Impact factor: 2.441

9.  Pharmacodynamic model for chemotherapy-induced anemia in rats.

Authors:  Sukyung Woo; Wojciech Krzyzanski; William J Jusko
Journal:  Cancer Chemother Pharmacol       Date:  2007-09-22       Impact factor: 3.333

10.  Pharmacodynamic model of interleukin-21 effects on red blood cells in cynomolgus monkeys.

Authors:  Rune V Overgaard; Mats Karlsson; Steen H Ingwersen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-05-22       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.